Product Center

Ruxolitinib Intermediate

Ruxolitinib sold under the brand names Jakafi, Jakavi, and Opzelura is a medication used for the treatment of intermediate or high-risk myelofibrosis,a type of myeloproliferative disorder that affects the bone marrow; polycythemia vera (PCV), when there has been an inadequate response to or intolerance of hydroxyurea and steroid-refractory acute graft-versus-host disease.Ruxolitinib is a Janus kinase inhibitor. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi and by Novartis elsewhere in the world, under the brand name Jakavi.